Savara Inc. (SVRA) News
Track canonical SquawkNews coverage tagged to SVRA, Savara Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Savara announces ERS 2026 encore presentations of Phase 3 APAP results
Savara says it will present encore results from the Phase 3 clinical trial of molgramostim inhalation solution in autoimmune pulmonary alveolar proteinosis at the European Respiratory Society Congress 2026.
EQUITY | Aug 24, 2026, 08:05 PM UTC
M
SVRA: MOLBREEVI MAAs Under Review
Savara says MOLBREEVI MAAs are under review by EMA and U.K.'s MHRA
EQUITY | Aug 11, 2026, 09:01 PM UTC
L
Savara Q2 EPS $(0.16) Misses $(0.14) Estimate
Savara (NASDAQ: SVRA ) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the sa
EARNINGS | Aug 11, 2026, 08:36 PM UTC
H
Savara: Europe, Australia Grant Molbreevi Patents
Savara gets patents for molbreevi in Europe and Australia
EQUITY | Jul 30, 2026, 12:28 PM UTC